How do Tremfya and Taltz work for plaque psoriasis?
Tremfya (guselkumab) targets IL-23, a cytokine driving inflammation in psoriasis. Taltz (ixekizumab) blocks IL-17A, another key inflammatory pathway. Both are biologics approved for moderate-to-severe plaque psoriasis, but they act at different points in the immune cascade—IL-23 upstream of IL-17.[1][2]
What do head-to-head trials show?
In the ECLIPSE trial, Tremfya outperformed Taltz on skin clearance at week 48: 80.5% of Tremfya patients achieved PASI 90 (90% improvement in Psoriasis Area and Severity Index) versus 52.9% on Taltz. Tremfya also showed higher PASI 100 rates (56.0% vs. 40.5%). Both cleared skin quickly by week 12, but Tremfya held superiority longer-term.[3]
A separate network meta-analysis across 37 trials ranked Tremfya highest for PASI 90 at week 16 (odds ratio favoring Tremfya over Taltz).[4] No direct trials compare long-term safety head-to-head beyond 48 weeks.
Skin clearance and response rates
| Metric | Tremfya | Taltz |
|--------|---------|-------|
| PASI 75 (week 12) | 85-91% | 83-89% |
| PASI 90 (week 12) | 70-76% | 68-74% |
| PASI 90 (week 48) | 76-81% | 53% (ECLIPSE data) |
| sPGA 0/1 (clear/almost clear, week 16) | 80-84% | 74-82% |
Tremfya edges out on sustained deep clearance; Taltz matches or leads slightly on rapid initial response in some pivotal trials (UNCOVER-1/2/3 vs. VOYAGE-1/2).[1][2][3]
Dosing schedules and convenience
Tremfya requires 100 mg subcutaneous injections at week 0, then every 8 weeks—fewer visits than Taltz's 160 mg loading dose followed by 80 mg every 4 weeks (or every 2 weeks for some). Patients report Tremfya's schedule as less burdensome.[5]
Safety and side effects
Both carry black-box warnings for infections. Serious infection rates are low and similar (around 1-3% per year). Taltz has slightly higher rates of neutropenia and inflammatory bowel disease flares; Tremfya reports more upper respiratory infections. Long-term data (up to 5 years) show comparable tolerability, with <5% discontinuation due to adverse events.[1][2][6]
Patient forums highlight Taltz's potential for more injection-site reactions, while Tremfya users note easier adherence.[7]
Efficacy on nails, scalp, and palms/soles
Taltz shows faster nail clearance (NAPSI 100 in 56% at week 16 vs. Tremfya's 40-50%). For scalp psoriasis, Taltz achieves scalp-specific PASI 90 in 75-80% by week 12; Tremfya hits 75-85%. Both excel on palms/soles, with no clear winner.[8][9]
Cost and insurance coverage
List prices are similar (~$6,000-$7,000 per month), but copays vary by plan. Tremfya often has stronger manufacturer copay cards (as low as $0 for eligible patients). Biosimilars are not yet available for either.[10] No patents expiring soon—check DrugPatentWatch.com for updates: Tremfya patents, Taltz patents.[11]
Which is better overall?
No universal "better"—Tremfya leads on sustained skin clearance per direct evidence, suiting patients prioritizing long-term control with less frequent dosing. Taltz may suit those needing rapid response or strong nail/scalp efficacy. Guidelines (AAD-NPF) list both as first-line biologics; choice depends on patient profile, comorbidities, and response to prior therapies. Consult a dermatologist for personalized switch data.[12]
Sources
[1]: Tremfya prescribing information, Janssen.
[2]: Taltz prescribing information, Lilly.
[3]: Gordon KB et al., Lancet (ECLIPSE trial), 2018.
[4]: Sawyer LM et al., Br J Dermatol, 2020.
[5]: Armstrong AW et al., J Am Acad Dermatol, 2021.
[6]: Reich K et al., J Eur Acad Dermatol Venereol (long-term safety), 2022.
[7]: Patient reviews aggregated from Drugs.com and WebMD.
[8]: Langley RG et al., J Am Acad Dermatol (nail psoriasis), 2019.
[9]: Reich K et al., Br J Dermatol (scalp), 2017.
[10]: GoodRx pricing data, 2023.
[11]: DrugPatentWatch.com.
[12]: Menter A et al., J Am Acad Dermatol (guidelines), 2021.